Research programme: cationic steroid therapeutics - CSA Biotech/N8 Medical

Drug Profile

Research programme: cationic steroid therapeutics - CSA Biotech/N8 Medical

Alternative Names: Ceragenins; CGX-313; CSA 90; CSA-13; CSA-54; CSA-8; CSAs

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Brigham Young University
  • Developer Brigham Young University; Ceragenix Pharmaceuticals; N8 Medical
  • Class Small molecules; Steroids
  • Mechanism of Action Cell membrane permeability enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Fracture
  • No development reported Bacterial infections
  • Discontinued Methicillin-resistant Staphylococcus aureus infections; Vaccinia; Viral infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (PO)
  • 04 Nov 2017 No recent reports of development identified for preclinical development in Bacterial-infections in USA (Topical)
  • 04 Mar 2015 Preclinical trials in Fracture in USA before March 2015 (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top